Progress in drug development has steadily improved survival from childhood malignant tumors over the past decades, but there is still a tremendous need for safe and effective drugs with which to treat pediatric cancers. Between 10% and 30% of children with cancer die within 5 years of diagnosis.1 Secondary tumors and treatment-related toxic effects, such as cognitive and endocrine dysfunctions, are also common among young survivors.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Arfè A, Silverman LB, Bourgeois F. Master Protocols and Adaptive Trial Designs to Develop Tumor-Agnostic Drugs for Children: Essential Tools in the Era of the Research to Accelerate Cures and Equity Act. JAMA Oncol. 2021;7(9):1281–1282. doi:10.1001/jamaoncol.2021.1508
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.